Molecular Net Income from 2010 to 2026
| MOLN Stock | USD 4.61 0.04 0.86% |
Net Loss | First Reported 2012-12-31 | Previous Quarter -20.4 M | Current Value -11.8 M | Quarterly Volatility 23.5 M |
Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular Partners' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 27.3 K or Selling General Administrative of 12.7 M, as well as many indicators such as Price To Sales Ratio of 20.99, Dividend Yield of 0.0 or PTB Ratio of 1.07. Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
Molecular | Net Income | Build AI portfolio with Molecular Stock |
Evaluating Molecular Partners's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Molecular Partners AG's fundamental strength.
Latest Molecular Partners' Net Income Growth Pattern
Below is the plot of the Net Income of Molecular Partners AG over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Molecular Partners financial statement analysis. It represents the amount of money remaining after all of Molecular Partners AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Molecular Partners' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Partners' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (54.04 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Molecular Net Income Regression Statistics
| Arithmetic Mean | (18,282,353) | |
| Geometric Mean | 17,904,344 | |
| Coefficient Of Variation | (242.19) | |
| Mean Deviation | 31,995,757 | |
| Median | (25,430,000) | |
| Standard Deviation | 44,278,440 | |
| Sample Variance | 1960.6T | |
| Range | 181.6M | |
| R-Value | (0.37) | |
| Mean Square Error | 1798.1T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | (3,283,112) | |
| Total Sum of Squares | 31369.3T |
Molecular Net Income History
Other Fundumenentals of Molecular Partners
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Molecular Partners Net Income component correlations
About Molecular Partners Financial Statements
Molecular Partners investors utilize fundamental indicators, such as Net Income, to predict how Molecular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -48.6 M | -46.2 M | |
| Net Loss | -62.1 M | -59 M | |
| Net Income Applicable To Common Shares | 135.5 M | 142.3 M | |
| Net Loss | (1.83) | (1.73) | |
| Net Income Per E B T | 1.15 | 1.10 |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
| 0.55 | DRMA | Dermata Therapeutics | PairCorr |
| 0.54 | VCEL | Vericel Corp Ord | PairCorr |
| 0.52 | PHARM | Pharming Group NV | PairCorr |
| 0.51 | RAC | Race Oncology | PairCorr |
| 0.48 | OSE | OSE Pharma SA | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Molecular Partners Correlation against competitors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Biotechnology sector continue expanding? Could Molecular diversify its offerings? Factors like these will boost the valuation of Molecular Partners. Expected growth trajectory for Molecular significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Molecular Partners data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Molecular Partners' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.